Quanterix ( (QTRX) ) has released its Q2 earnings. Here is a breakdown of the information Quanterix presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quanterix Corporation, a leader in ultra-sensitive biomarker detection, operates in the biotechnology sector, focusing on disease research, diagnostics, and drug development. The company recently announced its financial results for the second quarter of 2025, highlighting its strategic acquisition of Akoya Biosciences and advancements in Alzheimer’s diagnostics.
In the second quarter, Quanterix reported a revenue of $24.5 million, marking a 29% decrease from the previous year. The company faced a net loss of $30 million, a significant increase from the $7.4 million loss recorded in the same period last year. Despite these challenges, Quanterix’s Alzheimer’s Diagnostics revenues more than tripled year-over-year, and the company successfully launched new assays to advance Alzheimer’s research.
Strategically, Quanterix completed the acquisition of Akoya Biosciences, enhancing its platform capabilities. The company also achieved 75% of its $85 million synergy and cost reduction target, positioning itself for long-term growth. Quanterix anticipates achieving cash flow breakeven by 2026, even amid challenging market conditions.
Looking ahead, Quanterix expects to generate between $130 million and $135 million in revenue for the full year 2025, with a pro forma revenue projection of $165 million to $170 million, assuming the full-year integration of Akoya. The company remains focused on maximizing the potential of its recent acquisition and advancing its strategic initiatives.